FDA will review Primary Progressive MS treatment by the end of the year
July 8, 2016Ocrelizumab (trading as Ocrevus) had been submitted to the pharmaceutical regulators in the US and Europe, but in news closer to home, Roche has also announced that ocrelizumab has also been submitted to the Australian Therapeutic Goods Administration for both primary progressive and relapsing multiple sclerosis. To read more, click on the link below:
FDA will review Primary Progressive MS treatment by the end of the year
Article courtesy of MS Research Australia www.msra.org.au